The U.S. has stopped the production of AstraZeneca vaccine at a plant in Baltimore, where 15 million doses were spoiled due to an error in the production of Johnson & Johnson, the New York Times reported, citing high-ranking sources.
According to the newspaper’s interlocutors, the biotechnology company Emergent BioSolution will produce only one-component Johnson & Johnson vaccines to prevent mixing of vaccine ingredients in the future.
The decision came after it was revealed that Emergent BioSolutions, which works with both AstraZeneca and Johnson & Johnson, accidentally mixed ingredients from two different vaccines, forcing regulators to delay authorization of the plant’s production lines.
According to the newspaper, AstraZeneca said it would work with U.S. authorities to find an alternative manufacturing site.
Three vaccines are now approved for use in the United States: Pfizer/BioNTech, Moderna and Johnson & Johnson. Pfizer/BioNTech and Moderna deliver as planned. At the same time, the publication notes, Pfizer is even ahead of plan, and Moderna is waiting for approval to deliver vials with 15 doses instead of 10.
U.S. Chief Infectious Disease Officer Anthony Fauci previously said he did not see a need to use the AstraZeneca vaccine to fight the coronavirus, even if it is approved by a national regulator.
Currently, some EU countries have suspended vaccination with AstraZeneca’s drug because of reported thromboembolic complications in those vaccinated. The European regulator is investigating the incidents, but for now considers it possible to continue vaccination.
In the United States, the AstraZeneca vaccine has not yet been approved for use.